32 research outputs found
Anti‐inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154493/1/fsb2026005038.pd
Extracellular histones are essential effectors of C5aR‐ and C5L2‐mediated tissue damage and inflammation in acute lung injury
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154331/1/fsb2027012034.pd
Tyrosine kinase 2 promotes sepsis‐associated lethality by facilitating production of interleukin‐27
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/141056/1/jlb0123-sup-0001.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/141056/2/jlb0123.pd
Bidirectional Crosstalk between C5a Receptors and the NLRP3 Inflammasome in Macrophages and Monocytes
Complementâ induced activation of the cardiac NLRP3 inflammasome in sepsis
Cardiac dysfunction develops during sepsis in humans and rodents. In the model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), we investigated the role of the NLRP3 inflammasome in the heart. Mouse heart homogenates from shamâ procedure mice contained high mRNA levels of NLRP3 and ILâ 1β. Usingthe inflamm a some protocol, exposure of cardiomyocytes (CMs) to LPS followed by ATP or nigericin caused release of mature ILâ 1β. Immuno staining of left ventricular frozen sections before and 8 h after CLP revealed the presence of NLRP3 and ILâ 1β proteins inCMs. CLP caused substantial increases in mRNAs for ILâ 1β and NLRP3 in CMs which are reduced in the absence of either C5aR1 or C5aR2. After CLP, NLRP32/2 mice showed reduced plasma levels of ILâ 1βand ILâ 6. In vitro exposure of wildâ type CMs to recombinant C5a (rC5a) cause delevations in both cytosolic and nuclear/mitochondrial reactive oxygen species (ROS), which were C5aâ receptor dependent. Use of a selective NOX2 inhibitor prevented increased cytosolic and nuclear/mitochondrial ROS levels and release of ILâ 1β. Finally, NLRP32/2 mice had reduced defects in echo/Doppler parameters in heart afterCLP. These studies establish that the NLRP3 inflammasome contributes to the cardiomyopathy of polymicrobial sepsis.â Kalbitz, M., Fattahi, F., Grailer, J. J., Jajou, L., Malan, E. A., Zetoune, F. S., Huberâ Lang, M., Russell, M. W., Ward, P. A. Complementâ induced activation of the cardiac NLRP3 inflammasome in sepsis. FASEB J. 30, 3997â 4006 (2016). www.fasebj.orgPeer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154362/1/fsb2fasebj30120728r.pd
Role of extracellular histones in the cardiomyopathy of sepsis
The purpose of this study was to define the relationship in polymicrobial sepsis (in adult male C57BL/6 mice) between heart dysfunction and the appearance in plasma of extracellular histones. Procedures included induction of sepsis by cecal ligation and puncture and measurement of heart function using echocardiogram/Doppler parameters. We assessed the ability of histones to cause disequilibrium in the redox status and intracellular [Ca2+]i levels in cardiomyocytes (CMs) (from mice and rats). We also studied the ability of histones to disturb both functional and electrical responses of hearts perfused with histones. Main findings revealed that extracellular histones appearing in septic plasma required C5a receptors, polymorphonuclear leukocytes (PMNs), and the Nachtâ , LRRâ , and PYDâ domainsâ containing protein 3 (NLRP3) inflammasome. In vitro exposure of CMs to histones caused loss of homeostasis of the redox system and in [Ca2+]i, as wellas defects in mitochondrial function. Perfusion of hearts with histones caused electrical and functional dysfunction. Finally, in vivo neutralization of histones in septic mice markedly reduced the parameters of heart dysfunction. Histones caused dysfunction in hearts during polymicrobial sepsis. These events could be attenuated by histone neutralization, suggesting that histones may be targets in the setting of sepsis to reduce cardiac dysfunction.â Kalbitz, M., Grailer, J. J., Fattahi, F., Jajou, L., Herron, T. J., Campbell, K. F., Zetoune, F. S., Bosmann, M., Sarma, J. V., Huberâ Lang, M., Gebhard, F., Loaiza, R., Valdivia, H. H., Jalife, J., Russell, M. W., Ward, P. A. Role of extracellular histones in the cardiomyopathy of sepsis. FASEB J. 29, 2185â 2193 (2015). www.fasebj.orgPeer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154273/1/fsb2fj14268730.pd
Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.
Inhibitors of vascular endothelial growth factor and its receptors (VEGFRs) are attractive therapeutic candidates for cancer treatment. One such small molecule VEGFR inhibitor, SU5416, limits angiogenesis in vivo and is widely used for investigating VEGFR signaling in tumor pathophysiology. Herein, we describe novel actions of SU5416 on the immune system. Treatment of mice with SU5416 for 3 days induced significant reductions in size and cellularity of peripheral lymph nodes. Interestingly, SU5416 did not affect initial lymphocyte localization to peripheral lymph nodes but did reduce lymphocyte accumulation during long-term migration assays. Treatment with SU5416 also induced severe loss of double-positive thymocytes resulting in thymic atrophy and a reduction in peripheral B cells. Furthermore, immune responses following immunization were reduced in mice treated with SU5416. Findings of thymic atrophy and reduced weight gain during SU5416 treatment suggested elevated corticosterone levels. Indeed, a significant 5-fold increase in serum corticosterone was found 4 hours after treatment with SU5416. Importantly, adrenalectomy negated the effects of SU5416 treatment on primary immune tissues, and partial reversal of SU5416-induced changes was observed following blockade of glucocorticoid receptors. SU5416 has been reported to inhibit the activation of latent transforming growth factor (TGF)-β, a cytokine involved in the regulation of glucocorticoid release by the adrenal glands. Interestingly, treatment with a TGF-β receptor inhibitor, showed a similar phenotype as SU5416 treatment, including elevated serum corticosterone levels and thymic atrophy. Therefore, these results suggest that SU5416 induces glucocorticoid release directly from the adrenal glands, possibly by inhibition of TGF-β activation
Regulatory effects of C5a on IL-17A, IL-17F, and IL-23
The complement anaphylatoxin, C5a, through binding to its receptors (C5aR or C5L2), has important biological properties for recruitment and activation of phagocytes. C5a has been identified as a powerful modulator of TLR-induced cytokine and chemokine production by macrophages. Both the complement system and the IL-17 cytokine family protect against extracellular pathogens by enhancing innate immune functions. On the basis of its concentration, C5a can either positively or negatively modulate the production by macrophages of IL-17 family members as well as IL-23 via the PI3K/Akt signaling cascade. C5a can also affect the production and maintenance of IL-17-producing T cells. Using C5a, C5aR, or C5L2 deficiency or blockade, IL-17/IL-23 production and/or IL-17-dependent disease progression has been shown to be substantially modified. The contributions of C5a interaction with its receptors in the production of IL-17/IL-23 and promotion of IL-17-dependent immune responses are reviewed
Tissue cell counts and frequencies in SU5416 and RU486 treated mice<sup>a</sup>.
a<p>Mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. Some SU5416-treated mice were also treated with RU486 (50 mg/kg/day). Tissues were harvested after 3 days and labeled for flow cytometric analysis. Spleen and PLN were labeled for detection of CD4, CD8, and CD19 (B cells). Thymus was labeled for CD4 and CD8. Bone marrow was labeled for B220, IgM, and IgD. *Differences between vehicle and inhibitor-treated tissues were significant; p<0.05. <sup>†</sup>p = 0.052 vs. vehicle control.</p>b<p>Abbreviations used: DP, CD4 and CD8 double-positive; BM, bone marrow; PLN, peripheral lymph node; Pro/Pre, IgM<sup>-</sup>IgD<sup>–</sup> progenitor/precursor B cells; Imm, IgM<sup>+</sup>IgD<sup>–</sup> immature B cells; Mature, IgM<sup>+</sup>IgD<sup>+</sup> mature B cells.</p>c<p>Frequencies and total cell number of B cell populations in BM were calculated by gating on B220<sup>+</sup> cells.</p
Tissue cell counts and frequencies in adrenalectomized mice<sup>a</sup>.
a<p>Surgically adrenalectomized mice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle. Tissues were harvested after 3 days and labeled for flow cytometric analysis. Spleen and PLN were labeled for detection of CD4, CD8, and CD19 (B cells). Thymus was labeled for CD4 and CD8. Bone marrow was labeled for B220, IgM, and IgD. *Differences between vehicle and SU5416 were significant; p<0.05.</p>b<p>Abbreviations used: DP, CD4 and CD8 double-positive; BM, bone marrow; PLN, peripheral lymph node; Pro/Pre, IgM<sup>-</sup>IgD<sup>–</sup> progenitor/precursor B cells; Imm, IgM<sup>+</sup>IgD<sup>–</sup> immature B cells; Mature, IgM<sup>+</sup>IgD<sup>+</sup> mature B cells.</p>c<p>Frequencies and total cell number of B cell populations in BM were calculated by gating on B220<sup>+</sup> cells.</p